Cargando…
Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type I
Leukocyte adhesion deficiency type I (LAD-I) is a primary immunodeficiency caused by mutations in the ITGB2 gene, which encodes for the CD18 subunit of β(2)-integrins. Deficient expression of β(2)-integrins results in impaired neutrophil migration in response to bacterial and fungal infections. Usin...
Autores principales: | Mesa-Núñez, Cristina, Damián, Carlos, Fernández-García, María, Díez, Begoña, Rao, Gayatri, Schwartz, Jonathan D., Law, Ken M., Sevilla, Julián, Río, Paula, Yáñez, Rosa, Bueren, Juan A., Almarza, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418989/ https://www.ncbi.nlm.nih.gov/pubmed/36092365 http://dx.doi.org/10.1016/j.omtm.2022.07.015 |
Ejemplares similares
-
Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I
por: Leon-Rico, Diego, et al.
Publicado: (2016) -
Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment
por: Navarro, Susana, et al.
Publicado: (2021) -
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing
por: Cambon, Karine, et al.
Publicado: (2017) -
The downregulated membrane expression of CD18 in CD34(+) cells defines a primitive population of human hematopoietic stem cells
por: Mesa-Núñez, Cristina, et al.
Publicado: (2020) -
541 Intravenous Immunoglobulin in Leukocyte Adhesion Deficiency
por: Oropeza, Said Arablin, et al.
Publicado: (2012)